A Multi-Institutional Registry for CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)

NCT02457117 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-07-17

No results posted yet for this study

Summary

This study is a registry to monitor quality of life and clinical outcomes in patients with clinically localized breast cancer who have received stereotactic accelerated partial breast irradiation via CyberKnife.

Conditions

Interventions

RADIATION

CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)

Five fraction radiation therapy to the lumpectomy cavity

Sponsors & Collaborators

  • Georgetown University

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02457117 on ClinicalTrials.gov